On November 12, 2021, the U.S. Food and Drug Administration (FDA) approved ropeginterferon alfa-2b-njft for the treatment of adults with polycythemia vera.
Read the FDA announcement.
Read PharmaEssentia's announcement for more information.
Posted 11/15/2021
From mental health concerns to fertility preservation, adolescents and young adults with cancer require a specialized approach to treatment and survivorship care. In honor of Childhood Cancer Awareness Month, ACCC highlights a pivotal program from the University of North Carolina Lineberger Comprehensive Cancer Center and resources that meet the critical needs of these patients.
